BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tegobuvir: Phase IIb data

The double-blind, international Phase IIb Study 196-0103 trial in 252 non-cirrhotic treatment-naïve patients with chronic HCV genotype 1 infection showed that twice-daily 40 mg tegobuvir plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) for 48 weeks produced an rapid virologic response (RVR) rate, defined as HCV RNA levels <25 IU/mL at...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >